Allogeneic bone marrow transplantation for multiple myeloma.
Allogeneic bone marrow transplantation remains the only therapeutic approach with documented curative potential for patients with multiple myeloma. A survey of recently published trials reveals a 40% long-term survival rate with no evidence of residual disease in a majority of patients. While morbidity and mortality from myelosuppression and graft-versus-host disease are relatively high, allogeneic bone marrow transplantation should be considered early in the course of treatment for patients with high-risk myeloma.
Ballester
O F
OF
Division of Bone Marrow Transplantation, University of South Florida College of Medicine, Tampa 33612.
D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods; D003131:Combined Modality Therapy; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy*; D012074:Remission Induction; D016019:Survival Analysis; D014184:Transplantation, Homologous